Viridian Therapeutics, Inc.\DE
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
VRDN$30.19+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $212,382 | $99,594 |
| Marketable securities | 662,270 | 617,990 |
| Prepaid expenses and other current assets | 19,581 | 20,877 |
| Total current assets | 894,233 | 738,461 |
| Property and equipment, net | 1,228 | 1,236 |
| Operating lease right-of-use assets | 2,421 | 2,205 |
| Other assets | 1,536 | 501 |
| Total assets | $899,418 | $742,403 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,683 | $2,143 |
| Accrued liabilities | 62,013 | 45,731 |
| Total current liabilities | 70,696 | 47,874 |
| Long-term debt, net | 49,940 | 20,582 |
| Derivative liability | 20,030 | — |
| Liability related to the sale of future revenue, net | 34,244 | — |
| Other liabilities | 2,341 | 2,308 |
| Total liabilities | 177,251 | 70,764 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 134,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 61,188 | 61,188 |
| Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 79,620 and 145,160 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 70,868 | 127,697 |
| Common stock, $0.01 par value; 200,000,000 shares authorized; 101,826,500 and 80,994,046 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,018 | 810 |
| Additional paid-in capital | 1,927,104 | 1,477,811 |
| Accumulated other comprehensive income (loss) | 447 | (10) |
| Accumulated deficit | (1,338,458) | (995,857) |
| Total stockholders’ equity | 722,167 | 671,639 |
| Total liabilities and stockholders’ equity | $899,418 | $742,403 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.